Luke Maese, D.O., received his Bachelor’s degree in Human Biology from the University of Kansas and then went on to receive his degree in osteopathic medicine from Kansas City University. He completed his Paediatric residency at UPMC Children’s Hospital of Pittsburgh and Paediatric Haematology/Oncology fellowship at the University of Utah and Primary Children’s Hospital. He joined the faculty of the University of Utah School of Medicine in the Division of Paediatric Haematology/Oncology in 2015 where he currently serves as an Associate Professor on the Clinical Track. He cares for patients at both Primary Children’s Hospital (PCH) and Huntsman Cancer Institute (HCI).
Dr. Maese’s focus includes clinical care for children, adolescent/young adults (AYAs) with malignant hematopoietic disorders and clinical care of children, AYAs, and adults with cancer predisposition syndromes. He serves as director for the pediatric Leukemia/Lymphoma and paediatric Cancer Genetics programs, as well as the director of the Clinical Trial Research Enterprise and co-Director of the Bone Marrow Failure program within the division of paediatric haematology/oncology at PCH.
Dr. Maese’s interests in investigation are in paediatric acute lymphoblastic leukemia (ALL) and cancer predisposition syndromes. He is active in the Children’s Oncology Group (COG) ALL committee serving as a previous study chair of a phase 2/3 trial investigating recombinant Erwinia asparaginase, currently co-leading COG asparaginase-adjacent initiatives, and serving as the ALL committee’s liaison to the COG Young Investigator committee.
